https://www.mgmtinhibitor.com/2017/03/22/why-aml-patients-with-oncogenic-ras-advantage-most-from-high-dose-cytarabine-post-remission-therapy-is-just-not-well-understood-here-we-employed-bone-marrow-cells-expressing-a-conditional-mll-enl-er/